13F Holdings
中文EN

NRC NRC HEALTH

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 70487 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.4%
TTM net income YoY-60.6%
TTM EPS YoY6,909.9%
Revenue 3-yr CAGR-1.1%
Net income 3-yr CAGR-39.3%

Margins

Gross margin—
Operating margin11.1%
Net margin4.5%
FCF margin12.8%
EBITDA margin17.0%

Returns

ROE248.1%
ROA4.7%
ROIC (approx.)10.9%
Asset turnover1.05x

Leverage & solvency

Liabilities / assets106.6%
Debt / equity—
Current ratio0.64x
Interest coverage2.91x

Cash quality & payout

Operating cash flow / net income3.69x
Accruals ratio-12.6%
Payout ratio209.2%
Capex / revenue3.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$137.39M$143.06M$148.58M$151.57M$147.95M
SG&A expense$54.80M$44.91M$46.62M$42.70M$38.96M
Operating income$22.59M$35.19M$40.05M$46.54M$50.27M
Interest expense$4.76M$2.60M$862,000$1.21M$1.67M
Pretax income$17.84M$32.69M$39.96M$42.81M$48.62M
Income tax$6.25M$7.91M$8.99M$11.02M$11.15M
Net income$11.60M$24.78M$30.97M$31.80M$37.47M
EBITDA$30.21M$41.22M$45.94M——
EPS (basic)50.001.051.261.281.47
EPS (diluted)50.001.041.251.271.46
Dividends declared per share0.520.481.480.840.48
Weighted avg. shares (diluted)22.40M23.74M24.67M25.05M25.64M
Balance sheet
Cash & equivalents$4.14M$4.23M$6.65M$25.03M$54.36M
Receivables$11.11M$11.05M$12.38M$14.46M$13.73M
Current assets$20.21M$19.60M$24.36M$43.72M$73.71M
PP&E, net$40.47M$38.27M$28.20M$17.25M$12.39M
Goodwill$66.15M$66.15M$61.61M$61.61M$61.61M
Intangibles$2.23M$2.62M$1.47M$1.61M$1.79M
Total assets$134.88M$132.54M$122.44M$130.46M$157.54M
Current liabilities$36.62M$35.86M$36.20M$33.42M$40.39M
Short-term debt$4.01M————
Long-term debt$75.02M$57.90M$29.47M$22.32M$26.62M
Total debt$79.03M$57.90M$29.47M$22.32M$26.62M
Total liabilities$120.89M$101.25M$73.48M$58.43M$72.20M
Shareholders' equity$13.99M$31.28M$48.95M$72.03M$85.34M
Net debt$74.90M$53.66M$22.82M-$2.71M-$27.74M
Shares outstanding22.64M23.08M24.22M24.63M25.36M
Cash flow statement
Operating cash flow$26.45M$34.62M$38.11M$36.27M$46.34M
Capital expenditure$10.71M$15.45M$15.78M$9.84M$5.51M
Free cash flow$15.74M$19.18M$22.33M$26.43M$40.83M
Investing cash flow-$10.71M-$20.28M-$15.78M-$9.84M-$8.51M
Financing cash flow-$15.84M-$16.76M-$40.71M-$55.58M-$18.16M
Depreciation & amortization$7.62M$6.02M$5.90M——
Stock-based compensation$3.31M$284,000$935,000$1.20M$623,000
Dividends paid$10.98M$11.45M$36.37M$20.96M$9.16M
Share buybacks$20.18M$30.95M$19.10M$27.62M$4.14M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.